Pentadeca Arginate (PDA): Is It Really 'BPC-157 2.0'?
Last updated: November 4, 2026 · 11 min read · By the Grey Peptides Editorial Board
- The name 'pentadeca arginate' describes a fifteen-amino-acid peptide prepared as an arginine salt. Read that way it is BPC-157's chain with a different partner in the powder, but no study, regulator or journal defines PDA, so only a lab test can say what a vial holds 1 2.
- PubMed holds no study of pentadeca arginate or BPC-157 arginate. Any benefit claimed for PDA has to come from BPC-157 research, which we grade Low 1.
- FDA treats a peptide's free base and its acetate as different active ingredients, and in July 2026 it put a separate vote to each form of BPC-157. An arginate form was never nominated, evaluated or voted on 4 9.
- A stability advantage would solve a problem BPC-157's own developers say it does not have: they describe BPC-157 as stable in human gastric juice for more than 24 hours 3.
The short answer
Pentadeca arginate, abbreviated PDA, takes its name from what it is said to be: a fifteen-amino-acid peptide (pentadeca) made as an arginine salt (arginate). On that reading it is BPC-157's chain, a pentadecapeptide, with arginine in place of the usual partner. On the evidence available as of October 28, 2026, no study has examined it 1, and no FDA document names it 2.
A stability advantage would repeat a property BPC-157's developers already claim for BPC-157 3. And FDA's own documents treat each salt form of a peptide as a separate active ingredient, which leaves an arginate form outside even the July 2026 committee review that covered BPC-157's free base and acetate 4.
If PDA is BPC-157 as an arginate, it carries BPC-157's limited evidence and unresolved legal status with it, and sits further from the one regulatory route that might open.
What the name says
BPC-157 is a pentadecapeptide, a chain of fifteen amino acids: GEPPPGKPADDAGLV 5. The name "pentadeca arginate" says fifteen and arginate. Read literally, it is a fifteen-residue peptide prepared with arginine as its counter-ion. We found no regulator's record, journal paper or pharmacopoeia entry that defines it 1 2, so what a given vial contains can only be settled by testing it.
A counter-ion is the small partner that balances a peptide's charge in a dry powder. It does not change the sequence of amino acids, and that sequence is what every BPC-157 study tested. FDA, for its part, treats BPC-157 free base and BPC-157 acetate as different active pharmaceutical ingredients 4.
There is also a source of honest confusion. Many BPC-157 papers mention L-arginine, because the research group behind BPC-157 often studies it alongside the nitric oxide system. In those experiments L-arginine is a separate substance given to rats next to BPC-157, as in a 2022 study of heart injury that gave BPC-157, L-arginine and the nitric oxide blocker L-NAME alone or together 6. None of that work is about an arginine salt of BPC-157.
Why a different salt is not a different peptide
BPC-157's chain, GEPPPGKPADDAGLV, carries three acidic side groups, one glutamic acid and two aspartic acids, and one basic side group, a lysine 5. A basic partner such as arginine can pair with the acidic groups; acetate, an acid, pairs with the basic ones. Either way the chain is the same chain.
A salt's counter-ion separates from the peptide once the powder dissolves. What a reconstituted vial, a capsule or an injection delivers to the body is the fifteen-amino-acid chain, plus some free arginine or acetate. The arithmetic limits the arginine: arginine's molar mass is about 174 g/mol and BPC-157's about 1,419.5, so even if all three acidic groups carried one, it would come to about 0.37 milligrams of arginine per milligram of peptide (computed here).
A salt can still matter in the vial, which is why FDA evaluates salt forms separately 4. Whether an arginate powder is more stable than an acetate one is a question for a side-by-side test, and nobody has published one 1.
One practical consequence is worth spelling out. Arginine (about 174 g/mol) weighs nearly three times as much as acetate (about 60 g/mol), so if PDA and BPC-157 acetate are sold by weight, the same number of milligrams may hold different amounts of the actual peptide (computed here). Without a lab report stating peptide content, a buyer cannot know which.
What the evidence actually covers
We searched PubMed as of October 28, 2026 for "pentadeca arginate", "pentadecapeptide arginate", "BPC-157 arginate", "BPC 157 arginate" and "BPC157 arginate". Each search returned nothing 1. There is no animal study, no cell study and no human study of PDA as such.
Everything said about PDA's effects therefore comes from BPC-157, and BPC-157's own record is mostly animal work. A 2026 review written from a drug-development standpoint, with its search run to April 2026, found more than three decades of preclinical research, no approved formulation, no validated dosing regimen, no completed phase II trial, and clinical data from fewer than 30 people across three uncontrolled pilot studies, none using a standardised pharmaceutical preparation 5. FDA's May 2026 briefing counts more: it lists five clinical studies, in about 108 people, including a multicentre, randomised, double-blind, placebo-controlled study of BPC-157 enemas in ulcerative colitis that was reported only as a 2005 meeting abstract and whose data FDA judged inadequate to support efficacy or safety 4. A September 2026 report described three dental patients given BPC-157 with TB-500 and other drugs, without a control group 7.
The same review reports a plasma half-life under 30 minutes in animals and in a two-person human pilot, alongside effects in animals that last much longer, a gap it calls a disconnect with significant implications for dosing 5. That two-person pilot gave intravenous BPC-157 at a private clinic in Florida to two adults who had received it before, and reported no changes in heart, liver, kidney, thyroid or glucose markers 8. Two people is not a safety profile, and the product in that study was BPC-157, not an arginate salt.
FDA's briefing adds a further problem: the clinical articles it reviewed do not always say whether they used the free base or a salt, and it is often unclear which form a study used 4. If the literature cannot tell those two apart, it says nothing at all about a third form that it never mentions.
The stability argument
The argument for a new salt would be that BPC-157 acetate breaks down in stomach acid and an arginate survives. The trouble is that BPC-157's developers have said for years that BPC-157 itself survives stomach acid.
The group that first described BPC-157 calls it "native and stable in human gastric juice for more than 24 h" 3. FDA's briefing reports, citing a 1995 study, that BPC-157 was resistant to hydrolysis in gastric juice in the laboratory 4, and an independent 2026 review repeats that BPC-157 shows unusual stability in gastric juice and reports activity by oral, injected and topical routes 5. Those claims concern BPC-157 as studied, not an arginate.
So a stability claim for PDA would contradict the parent literature it borrows from. Either BPC-157 is stable in gastric juice, as its developers say, in which case an arginate solves nothing; or it is not, in which case the oral results it borrows were never real either. Neither version gives PDA an advantage that has been shown.
What would settle it is unglamorous: the two salts side by side, in acid, at body temperature, measured by a validated method, and then in people, with blood levels. None of that exists 1. The 2026 review notes that BPC-157 lacks even classification data, permeability characterisation and formal excipient compatibility studies 5, which is the work that comes before any claim about a better formulation.
The regulatory logic
An arginate's appeal to compounders would rest on an idea: that a different salt is a different substance, outside the restrictions on BPC-157. FDA's own documents show why that idea cuts the other way.
When FDA prepared BPC-157 for its Pharmacy Compounding Advisory Committee, its briefing stated that BPC-157 acetate and BPC-157 free base are different active pharmaceutical ingredients. Because the nominations were inconsistent about which was meant, FDA evaluated both on its own initiative. It also recorded that neither form has a USP or NF monograph or is a component of an approved drug, and that "BPC-157" is a common name, not a United States Adopted Name; FDA's evaluation weighed against placing either form on the list 4. The questions put to the committee on July 23, 2026 asked two separate votes: whether BPC-157 free base should go on the list, and whether BPC-157 acetate should 9. FDA has posted no tallies; a law firm's summary reports that the committee recommended BPC-157 by 8 votes to 6, with 1 abstention 10, and our PCAC hub sets out the full result.
An arginate appears nowhere in that process 4 9. If the free base and the acetate are different ingredients, an arginate is a third one.
That matters because of how compounding law works. Under section 503A, a bulk drug substance must meet a USP or NF monograph, be a component of an approved drug, or appear on FDA's 503A bulks list; FDA's interim policy also says it does not intend to act against compounding with Category 1 substances on its nominated list, and excludes Category 2 and Category 3 substances from that policy 11. An arginate of BPC-157 meets none of these 4. FDA's nominated-substances list, read as of October 28, 2026, reads "Updated May 14, 2026" and contains no entry for BPC-157 in any form or for any arginate 12. The Federal Register shows no FDA document on 503A bulk drug substances since July 1, 2026 13, and a search found no FDA document that names pentadeca arginate at all 2.
So a pharmacy offering an arginate of BPC-157 is in at least as weak a position as one offering BPC-157. If FDA does act on the committee's recommendation, its documents name the free base and the acetate, and a decision on those two forms would not, on its face, cover an arginate 9.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 14. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales; it names BPC-157 only as the acetate, so an arginate salt is outside it (our fact check).
The same logic runs through the rest of that meeting. TB-500 and KPV were also put to separate votes on their free base and acetate forms 9, so any other salt of them would sit outside the review in the same way.
In tested sport
WADA's Prohibited List names BPC-157 under S0, its section for substances with no current approval for human therapeutic use, prohibited at all times 15. The listing names the substance, not a salt form, so an athlete taking a product that is BPC-157's chain as an arginate should expect it to be treated as BPC-157.
BPC-157's regulatory history
FDA placed BPC-157 in Category 2 of its interim policies, for nominated substances that raise significant safety risks; its safety-risks page now lists it among substances previously in Category 2 whose nominations were withdrawn. FDA's summary says compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration and that FDA has identified no, or only limited, safety-related information for the proposed routes 16.
We built a name decoder for product names like this one, with PDA among the names it covers.
What to ask if someone offers you PDA
Three questions cut through most of it.
- What is the sequence? If the answer is GEPPPGKPADDAGLV, the product is BPC-157 5, and everything on our BPC-157 entry applies to it: the evidence grade, the regulatory status and the anti-doping status.
- How much of the weight is peptide? A lab report should state peptide content, not just purity, because a salt's partner adds weight. Our COA decoder explains what a credible report contains.
- Under which legal route is it made? For a pharmacy, as of October 28, 2026, an arginate salt of BPC-157 has no monograph, is in no approved drug, is not on the 503A bulks list and is not in Category 1 11 12 4.
None of this tells you whether BPC-157 works for any particular condition; that question is open, and its evidence is mostly in animals 5 4. What it does tell you is that PDA adds nothing to the answer.
Frequently asked questions
Is pentadeca arginate the same as BPC-157?
Its name describes a fifteen-amino-acid peptide made as an arginine salt, which would be BPC-157's chain, GEPPPGKPADDAGLV, with a different counter-ion. No study or regulator defines PDA, so only a lab test can confirm what a product contains.
Is PDA more stable than BPC-157?
No published study shows it. PubMed holds no study of PDA, and BPC-157's own developers already describe BPC-157 as stable in human gastric juice for more than 24 hours.
Can a pharmacy legally compound PDA?
As of October 28, 2026, no 503A route covers it. FDA treats a peptide's free base and acetate as different active ingredients, and its July 2026 committee review covered only those two forms of BPC-157; an arginate was never nominated, has no monograph, and is in no approved drug.
Has PDA been studied in people?
No. A PubMed search on October 28, 2026 for pentadeca arginate and BPC-157 arginate returned no records. FDA's May 2026 briefing lists five clinical studies of BPC-157 itself and judged the data inadequate.
Is PDA allowed in sport?
WADA names BPC-157 under S0 of its Prohibited List. The listing names the substance, not a salt, so a product that is BPC-157's chain should be expected to be treated as BPC-157.
Related on Grey Peptides
- BPC-157 encyclopedia entry
- Can a doctor prescribe BPC-157 in 2026?
- PCAC July 2026 hub
- Gray-market name decoder
- KLOW vs GLOW vs Wolverine
Sources
- PubMed searches for "pentadeca arginate", "pentadecapeptide arginate", "BPC-157 arginate", "BPC 157 arginate" and "BPC157 arginate", run October 1 and re-run October 28, 2026: no records for any of them. PubMed
- Searches for "pentadeca arginate", "pentadecapeptide arginate" and "BPC-157 arginate" on fda.gov (October 1, 2026) and the web (October 28, 2026): no FDA document, journal paper or other regulator's page found; the only pages found were commercial.
- Sikiric, P. et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PMID: 38980576
- U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee, dated May 11, 2026: different active pharmaceutical ingredients, both evaluated on FDA's initiative, no monograph, no approved drug, five clinical studies; read October 1 and re-read October 28, 2026. FDA
- Mateescu, D. M. et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. PMID: 42198317
- Barisic, I. et al. (2022). Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines. PMID: 35203478
- Froum, S. et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
- Lee, E. et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. PMID: 40131143
- U.S. Food and Drug Administration. Questions for the Pharmacy Compounding Advisory Committee, July 23-24, 2026, with separate votes on the free base and the acetate of each substance; no arginate named. Re-read October 28, 2026. FDA
- McDermott Will & Schulte (law firm). Bulk list bound? PCAC backs majority of peptides in two-day public meeting, July 27, 2026: BPC-157 8-6-1. A law-firm summary, not an FDA record; FDA has posted no tallies. Read October 27, 2026. Cited without a link.
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for industry, January 2025: the three statutory routes; Category 1 policy; Categories 2 and 3 excluded. Re-read October 28, 2026. FDA
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3). Updated May 14, 2026; re-read October 28, 2026, with no entry for BPC-157 or any arginate. FDA
- Federal Register API. FDA documents matching "503A" bulk drug substances published since July 1, 2026: none (64 in all; newest May 1, 2026). Checked October 28, 2026. Federal Register
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0, non-approved substances, prohibited at all times, which names BPC-157. Read October 28, 2026. WADA
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: BPC-157, in the table of substances previously in Category 2 whose nominations were withdrawn. Content current as of April 22, 2026; re-read October 28, 2026. FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. This article describes chemistry, evidence and regulatory status; it is not legal or medical advice.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead